Nicotinamide mononucleotide supplementation modulates gut microbiota and metabolites to mitigate Alzheimer’s disease pathology in APP/PS1 mice.

This study tested NMN supplementation in mice with Alzheimer’s disease and found it improved both gut health and brain function. NMN restored healthy gut bacteria balance, reduced brain inflammation, and enhanced memory performance in the test animals. The research suggests NMN works through a gut-brain connection, improving the intestinal barrier while also protecting brain cells from damage. These findings indicate NMN may offer a dual approach to supporting both digestive and cognitive health.

For your business

NMN supplementation shows promise for supporting both gut health and cognitive function simultaneously through the gut-brain axis.

Read more on Journal of Alzheimer’s disease : JAD →

Scroll to Top